Growth Metrics

GeneDx Holdings (WGS) Change in Receivables (2020 - 2026)

GeneDx Holdings has reported Change in Receivables over the past 7 years, most recently at $2.6 million for Q1 2026.

  • Quarterly Change in Receivables fell 70.11% to $2.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.2 million through Mar 2026, up 68.36% year-over-year, with the annual reading at $36.2 million for FY2025, 599.44% up from the prior year.
  • Change in Receivables was $2.6 million for Q1 2026 at GeneDx Holdings, down from $13.4 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $13.4 million in Q4 2025 and troughed at -$13.5 million in Q2 2022.
  • The 5-year median for Change in Receivables is -$36000.0 (2022), against an average of $1.6 million.
  • The largest YoY upside for Change in Receivables was 2359.42% in 2024 against a maximum downside of 435.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$36000.0 in 2022, then soared by 655.56% to $200000.0 in 2023, then tumbled by 435.0% to -$670000.0 in 2024, then soared by 2104.78% to $13.4 million in 2025, then crashed by 80.96% to $2.6 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Change in Receivables are $2.6 million (Q1 2026), $13.4 million (Q4 2025), and $12.9 million (Q3 2025).